Global Mucosal Atomization Devices Market

Prosthetic heart valve devices and equipment are artificial heart valves that are implanted in the heart of a patient with valvular heart disease. The main types of prosthetic heart valve devices and equipment are transcatheter heart valve, tissue heart valve, and mechanical heart valve. Transcatheter aortic valve replacement is an invasive heart procedure to replace a thickened aortic valve that will not fully open. The product types are repair products, mitral valve repair devices, and tricuspid valve repair devices. The technologies involved in prosthetic heart valve devices and equipment are biological valves and decellularized valves that are used in various applications such as hospitals and ambulatory surgery centres. The prosthetic heart valve devices and equipment market research report is one of a series of new reports from The Business Research Company that provides prosthetic heart valve devices and equipment market statistics, including prosthetic heart valve devices and equipment industry global market size, regional shares, competitors with a prosthetic heart valve devices and equipment market share, detailed prosthetic heart valve devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the prosthetic heart valve devices and equipment industry. This prosthetic heart valve devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global prosthetic heart valve devices and equipment market size will grow from $5.04 billion in 2022 to $5.5 billion in 2023 at a compound annual growth rate (CAGR) of 9.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The prosthetic heart valve devices and equipment market size is expected to grow to $7.41 billion in 2027 at a CAGR of 7.7%. The rising prevalence of valvular heart disease has driven the need for transcatheter aortic valve replacement (TAVR) procedures, thus driving the prosthetic heart valve devices and equipment market. TAVR is a minimally-invasive surgical procedure done to cure aortic stenosis which is a valvular heart disease that affects the aortic valve of the heart. Aortic stenosis affects the aortic valve by hardening it, thus not allowing blood to properly flow through it and TAVR is used to replace this defective aortic valve with a transcatheter valve. According to a report from The Society of Thoracic Surgeons (STS)/American College of Cardiology (ACC) TVT Registry, volumes have grown every year. In 2021, TAVR procedures make up more than 84% of aortic valve replacement procedures in the united states. 92,000 TAVR procedures were done in 2021. As the rate of occurrence of valvular heart diseases rises, the number of TAVR procedures done can be expected to increase which also increases the demand for transcatheter valves, thus driving the market going forward. Prosthetic heart valve devices have stringent procedures for approval which restrains the growth of the prosthetic heart valve devices and equipment market. According to the US food and drugs administration (FDA), randomized clinical trials are required for any medical device, to test for its safety standards. A randomized clinical trial is a clinical method of study that involves the separation of groups of patient subjects using random selection. This is done to compare different medicines and treatment methods fairly with no room for bias and also to detect side effects if any. However, these random clinical trials take long periods. Companies in this market are increasingly preferring polymer valves over traditional mechanical and bio-prosthetic valves/tissue valves. Polymer heart valves are prosthetic heart valves made of polymeric materials and have better functioning than tissue and mechanical heart valves. Mechanical heart valves come with a lifelong requirement of using blood-thinning medication to prevent blood clotting whereas bioprosthetic heart valves come with a short life span that needs several replacements and have a risk of valve degradation. Polymeric heart valves on the other hand support better blood flow and reduce the risk of blood clotting and therefore do not have the disadvantages of tissue and mechanical valves. Therefore, various companies are focusing on the development of polymeric heart valve technologies, For instance, in July 2022, Shanghai Medics, a Shanghai-based medical technology company developed new synthetic heart valve. The new valve is developed using polymer nanomaterial and has a longer lasting life of 20 to 25 years. The prosthetic heart valve devices and equipment market is monitored by regulatory bodies such as FDA in the US and The Central Drugs Standard Control Organization (CDSCO). For instance, CDSCO issued a notice regarding the classification of the risk levels of different medical devices. Under this classification, prosthetic heart valves are considered a class D or high-risk device. Similarly, for manufacturers to produce and sell prosthetic valve devices in India, they need to sign forms MD-7 and MD-8 which come under the direct purview of the central government of India. Form MD-7 is used to register prosthetic valve manufacturers in India and form MD-8 is used by prosthetic valve manufacturers to apply for loans. Major players in the prosthetic heart valve devices and equipment market are Boston Scientific, Edward life sciences, Medtronic, Livanova, Abbott, Jenavalve technology, Lepu medical, Cryolife, Neovasc Inc., and St. Jude medical. North America was the largest region in global prosthetic heart valve devices and equipment market in 2022. Western Europe was the second-largest region in prosthetic heart valve devices and equipment market. The regions covered in the global prosthetic heart valve devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the prosthetic heart valve devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. The prosthetic heart valve devices and equipment market consist of sales of mechanical heart valves, transcatheter heart valves, and tissue heart valves that are used for heart patients. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global prosthetic heart valve devices and equipment market is segmented - 1) By Type: Transcatheter Heart Valve, Tissue Heart Valve,  Mechanical Heart Valve 2) By Application: Hospitals, Ambulatory Surgery Centres 3) By Product Type: Repair Products, Mitral Valve Repair Devices, Tricuspid Valve Repair Devices 4) By Technology: Biological Valve, Decellularized Valve

Benign prostatic hyperplasia or benign prostatic hypertrophy is a condition of prostate gland enlargement which causes blockade of urethra, the tube that carries urine from the bladder. The main products in the benign prostatic hyperplasia (BPH) treatment devices and equipment market are resectoscopes, radiofrequency ablation devices, urology lasers, prostatic stents, and implants. A resectoscope is an endoscope that is used for surgeries on the uterus, prostate, bladder, or urethra. The device helps in extracting tissue for biopsy, removing growths, or ablating diseased or damaged tissue. The various procedure types are transurethral needle ablation (TUNA), transurethral resection of the prostate (TURP), transurethral incision of the prostate (TUIP), transurethral microwave thermotherapy (TUMT), laser surgery, and others. The various end-users involved are hospitals, ambulatory surgical centres (ASC), clinics, homes. The benign prostatic hyperplasia (BPH) treatment market research report is one of a series of new reports from The Business Research Company that provides benign prostatic hyperplasia (BPH) treatment market statistics, including benign prostatic hyperplasia (BPH) treatment industry global market size, regional shares, competitors with a benign prostatic hyperplasia (BPH) treatment market share, detailed benign prostatic hyperplasia (BPH) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the benign prostatic hyperplasia (BPH) treatment industry. This benign prostatic hyperplasia (BPH) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global benign prostatic hyperplasia (BPH) treatment devices and equipment market size will grow from $1.49 billion in 2022 to $1.62 billion in 2023 at a compound annual growth rate (CAGR) of 8.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global benign prostatic hyperplasia (BPH) market size is expected to grow to $2.09 billion in 2027 at a CAGR of 6.6%. Benign Prostatic Hyperplasia (BPH) also called Prostate Gland Enlargement (PGE), is a condition where the patient suffers from uncomfortable urinary symptoms. Due to the rising prevalence of Benign Prostatic Hyperplasia (BPH), demand for the BPH treatment devices and equipment is on a steady rise as the number of BPH cases increases the demand for devices will also increase. For example, in 2021, more than 14 million men in the United States have symptoms of BPH. Globally 30 million men have symptoms related to BPH. Therefore, with the number of BPH cases on the steady rise, the demand for BPH treatment devices and equipment is also expected to grow. The side effects suffered by the patients after a BPH procedure are one of the major restraints for the BPH device and equipment market. For example, the most common side effects of a BPH surgery include urinary incontinence, discomfort during urination, and difficulty in completely emptying the bladder. The patients suffering from BPH do not prefer surgical procedures (till the stage it can be avoided) due to these side effects, therefore decreasing the demand for surgical procedures, which in turn limits the demand for devices used by end-users like hospitals, clinics, and ambulatory surgical centres. Prostatic Artery Embolization (PAE) is one of the latest developments in the market for Benign Prostatic Hyperplasia (BPH) treatment devices and equipment. PAE is a minimally invasive treatment that assists in reducing the symptoms observed in the urinary tract. The PAE procedure is done using X-rays and other advanced imaging to observe the tumor inside the body and accordingly treat it without any surgery. This technique results in reduced complications in the treatment of BPH and thus is said to be a major development in the market of BPH treatment. Leading companies such as Boston scientific, UNC healthcare, and Spire healthcare have been investing in the market for PAE Product recall is a process of retrieving all defective products that have been sold or are available in the market. When a company recalls a product from the market, the company bears all the cost of fixing the defective product and the cost of replacement. This cost of replacement for large companies can go up to a multi-million dollars, hence restraining the growth of the company and for the whole market as well. Product recall is one of the major hurdles for any market, Benign Prostatic Hyperplasia (BPH) Treatment Devices, and Equipment market is no exception. For example, in the year 2021, Arrow International recalled Arrow-Trerotola over-the-wire PTD kit percutaneous Thrombolytic device due the risk of separation. In March 2021, Olympus exercises, a Japan-based company manufacturer of optics and reprography products acquired Medi-Tate for an undisclosed amount. This acquisition of Medi-Tate to drive growth in its urology business and expand its minimally invasive treatment product portfolio. Medi-Tate is an Israeli medical device company for improves men's healthcare and quality of life through effective, non-surgical solutions. Major players in the benign prostatic hyperplasia (BPH) treatment devices and equipment market are Karl Storz, Lumenis, Olympus, Urologix, Boston Scientific Inc., Endo International, Neo tract, Lisa Laser, Medifocus Inc., ProArc Medical LTD., and Olympus America. North America was the largest region in the benign prostatic hyperplasia (BPH) treatment devices and equipment market in 2022. Western Europe was the second largest region in the global benign prostatic hyperplasia (BPH) treatment devices and equipment market. The regions covered in the global benign prostatic hyperplasia (BPH) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the benign prostatic hyperplasia (BPH) treatment devices and equipment market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The benign prostatic hyperplasia (BPH) treatment devices and equipment market consist of sales of prostatic stents, catheter ablation devices, resectoscopes, radiofrequency ablation devices, urology lasers, and prostatic stents that are used to treat benign prostatic hyperplasia. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global benign prostatic hyperplasia (BPH) treatment devices and equipment market is segmented - 1) By Product: Resectoscopes, Radiofrequency Ablation Device, Urology Lasers, Prostatic Stents, Implants 2) By End-User: Hospitals, Ambulatory Surgical Centres (ASC), Clinics, Home 3) By Procedure Type: Transurethral Needle Ablation (TUNA), Transurethral Resection Of Prostate (TURP), Transurethral Incision Of Prostate (TUIP), Transurethral Microwave Thermotherapy (TUMT), Laser Surgery, Other Procedure Types

Cardiovascular monitoring and diagnostic devices and equipment are used for the diagnosis, monitoring, and treatment of cardiovascular diseases. The main product types of cardiovascular monitoring and diagnostic devices and equipment are cardiopulmonary stress testing systems, ECG data management systems, ECG monitoring equipment, ECG stress testing systems, event monitoring systems, and Holter monitoring systems. ECG monitoring equipment is an electronic device that is used to record the electrical activity of the heart. The various types involved are heart disease and coronary heart disease. The various end-users involved are hospitals/physician clinics (continuous glucose monitors), home/emergency, and research and development (clinical trials, universities, CRO). The cardiovascular monitoring and diagnostic devices and equipment market research report is one of a series of new reports from The Business Research Company that provides cardiovascular monitoring and diagnostic devices and equipment market statistics, including cardiovascular monitoring and diagnostic devices and equipment industry global market size, regional shares, competitors with a cardiovascular monitoring and diagnostic devices and equipment market share, detailed cardiovascular monitoring and diagnostic devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the cardiovascular monitoring and diagnostic devices and equipment industry. This cardiovascular monitoring and diagnostic devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global cardiovascular monitoring and diagnostic devices and equipment market size will grow from $3.12 billion in 2022 to $3.36 billion in 2023 at a compound annual growth rate (CAGR) of 7.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cardiovascular monitoring and diagnostic devices and equipment market size is expected to grow to $4.31 billion in 2027 at a CAGR of 6.4%. The cardiovascular monitoring and diagnostic devices and equipment market is being driven by an increasing number of people suffering from obesity and diabetes. Risk factors including high blood pressure and high cholesterol are associated with obesity and diabetes leads to cardiovascular diseases. For instance, as per a study conducted by the American Heart Association (AMA), by 2030, 22.2 million CVD is expected to grow. According to another study conducted by AMA in the U.S., 26 million people have been diagnosed with diabetes, and above 9 million further, have the condition but it hasn't yet been diagnosed. The cardiovascular monitoring and diagnostic devices and equipment market is being restrained by the FDA's regulatory control over these devices based on the risks associated with this equipment. Cardiovascular monitoring and diagnostic devices fall into the class II category as per the FDA, which includes devices with moderate to high risk associated with usage. The Class II devices are specially controlled with performance standards which provide the manufacturers with performance specifications, postmarket surveillance which monitors the safety of the device after being released in the market, and also other standards like patient registries and special labeling requirements. For instance, Angel medical systems’ implantable cardiac monitor was unanimously rejected by a panel of FDA experts due to unmet performance specifications. ICMs continuously monitor the electrocardiogram (ECG) of the patient to conduct a real-time examination of the heart rhythm, for up to 36 months. ICMs are mostly used in the analysis of transitory symptoms which have an arrhythmic origin, such as unexplained palpitations. For example, in July 2020, Medtronic received U.S. Food and Drug Administration (FDA) clearance and European CE label approval for its Linq II insertable cardiac monitor (ICM) by remote programming, allowing clinicians to optimize device settings without the requirement for patients to return to the hospital. The launch of new products is a key trend gaining popularity in the cardiovascular monitoring and diagnostic devices and equipment market. Companies in the market are focusing on the launch of new products to improve their product portfolio and strengthen their market position. For example, in August 2022, SmartCardia SA, a medical equipment manufacturer in Switzerland, launched 7L patch, its 7-lead cardiac monitoring patch in India. This patch monitor combines medical wearable technology with artificial intelligence (AI) to provide predictive and personalized patient insights through remote monitoring. The 7L patch is tracked by SmartCardia’s AI platform is interpreted by cardiologists and certified cardiac technicians and performs real-time detection of important arrhythmia events at cardiologist level accuracy. The US FDA has classified cardiovascular monitoring and diagnostic devices into the Class II category, as they have a moderate to high risk associated with usage. Class II devices are bounded by device-specific regulations which include performance standards, premarket data requirements, postmarket surveillance, and labeling requirements associated with device usage. For instance, the labeling should consist of contraindications, adverse reactions, precautions, warnings, and other instructions before the device is released into the market. Major players in the cardiovascular monitoring and diagnostic devices and equipment market are Medtronic PLC., Boston Scientific Corporation, GE Healthcare, Johnson & Johnson, Philips Healthcare, Siemens Healthcare, St. Jude MedicalInc., Nihon Kohden Corporation, FUKUDA DENSHI Co. Ltd., and Sorin Group. North America was the largest region in global cardiovascular monitoring and diagnostic devices and equipment market in 2022. Western Europe was the second-largest region incardiovascular monitoring and diagnostic devices and equipment market. The regions covered in global cardiovascular monitoring and diagnostic devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cardiovascular monitoring and diagnostic devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. The cardiovascular monitoring and diagnostic devices and equipment market consist of sales of cardiopulmonary stress testing systems, ECG data management systems, ECG monitoring equipment, ECG stress testing systems, event monitoring systems, and holter monitoring systems that are used for diagnosis and treatment of cardio diseases. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global cardiovascular monitoring and diagnostic devices and equipment market is segmented - 1) By Product Type: Cardiopulmonary Stress Testing Systems, ECG Data Management Systems, ECG Monitoring Equipment, ECG Stress Testing Systems, Event Monitoring Systems, Holter Monitoring Systems 2) By End-Use: Hospitals/Physician Clinic (Continuous Glucose Monitors), Home/Emergency, Research and Development (Clinical Trials, Universities, CRO) 3) By Type: Heart Disease, Coronary Heart Disease

Weight monitoring and body temperature monitoring devices and equipment are the devices used or employed in establishing the size, quantity, extent, area, or measurement of quantities, things, produce, or articles for distribution or consumption that are sold or exposed for sale or hire at any basic charge, and a temperature monitoring system controls and regulates the temperature of a particular environment.  The main types of weight monitoring and body temperature monitoring devices and equipment are weight monitoring devices and temperature monitoring devices. Weight monitoring devices are the devices used or employed in establishing the size, quantity, extent, area, or measurement of quantities, things, produce, or articles for distribution or consumption that are sold or exposed for sale or hire at any basic charge. The temperature monitoring devices are tabletop temperature monitoring devices, handheld temperature monitoring devices, wearable continuous monitoring thermometers, temperature monitoring sensors, and smart temperature patches. The various end-users include hospitals and clinics, home settings, and ambulatory surgical centres. The weight monitoring and body temperature monitoring devices and equipment market research report is one of a series of new reports from The Business Research Company that provides weight monitoring and body temperature monitoring devices and equipment market statistics, including weight monitoring and body temperature monitoring devices and equipment industry global market size, regional shares, competitors with a weight monitoring and body temperature monitoring devices and equipment market share, detailed weight monitoring and body temperature monitoring devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the weight monitoring and body temperature monitoring devices and equipment industry. This weight monitoring and body temperature monitoring devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global weight monitoring and body temperature monitoring devices and equipment market size will grow from $8.04 billion in 2022 to $9.07 billion in 2023 at a compound annual growth rate (CAGR) of 12.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The weight monitoring and body temperature monitoring devices and equipment market size is expected to grow to $13.91 billion in 2027 at a CAGR of 11.3%. The rising prevalence of obesity is one of the major drivers of the weight monitoring devices and equipment market. According to the World Health Organization (WHO), 1.9 billion adults around the globe were diagnosed, as overweight, and also over 340 million children of 5 to 19 years across the globe were overweight. To curb the increase of obesity, weight monitoring devices can play a vital role by reminding the user to follow a certain diet or monitor the exercising habits of the individual. Thereby driving the demand for weight monitoring devices, thus driving the market growth. Product recalls act as a restraint on the weight monitoring and body temperature monitoring devices and equipment market. For instance, the US Food and Drug Administration (FDA) has recalled many digital thermometers due to wrong calibration and incorrect display of body temperature. Also, thermometers manufactured by 3M company were recalled by the FDA after a prolonged investigation due to incorrect display of body temperature. Similarly, in 2020, the FDA has recalled a specific model electric thermometer manufactured by Cardinal Health, a multinational health care services company. Such a high number of product recall hampers the market growth. The use of wearables is a trend that is prevalent in the weight monitoring and body temperature monitoring devices and equipment market. Many companies such as Apple, Google, and Samsung are investing in the research and development of wearables. The wearables have high-end sensors attached to them, which measures and monitors body temperature and weight. Various new products are launched in the wearable category. For example, Blue Spark's, Temp Traq is a wearable temperature monitor. Also, Fitbit wearable tracks and monitor weight. Stringent FDA regulations need to be followed in the weight monitoring and body temperature monitoring devices and equipment market. FDA has a set of good manufacturing practices designed for the monitoring of body temperature and weight monitoring devices. FDA monitors the safety and effectiveness of these devices. Part 880 of the FDA regulations pertain to the general hospital and personal use devices; subpart C relates to personal use monitoring devices. Weight monitoring devices are classified by the FDA as Class I devices. The manufacturers are tasked with the thorough inspection, measuring and testing efficiency, and ensuring it meets the intended purposes. Once this is finished the manufacturer must calibrate the device according to a set of rules or limits to improve the precision and accuracy of the readings. After all, this is completed the FDA will take their final call regarding the certification of the device. Major players in the weight monitoring and body temperature monitoring devices and equipment market are Philips Healthcare, Medtronic, GE Healthcare, Abbott Laboratories, 3M, Nihon Kohden, Omron Healthcare, Siemens Healthcare, Honeywell International Inc., and Infinium Medical. Asia-Pacific was the largest region in the global weight monitoring and body temperature monitoring devices and equipment market in 2022. North America was the second-largest region in the weight monitoring and body temperature monitoring devices and equipment market. The regions covered in the global weight monitoring and body temperature monitoring devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the weight monitoring and body temperature monitoring devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. The weight monitoring and body temperature monitoring devices and equipment market consist of sales of table-top temperature monitoring devices, handheld temperature monitoring devices, wearable continuous monitoring thermometers, temperature monitoring sensors, and smart temperature patches. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global weight monitoring and body temperature monitoring devices and equipment market is segmented - 1) By Type: Weight Monitoring Devices, Temperature Monitoring Devices 2) By End User: Hospitals & Clinics, Home Settings, Ambulatory Surgical Centers 3) By Temperature Monitoring Devices: Table Top Temperature Monitoring Devices, Hand Held Temperature Monitoring Devices, Wearable Continuous Monitoring Thermometers, Temperature Monitoring Sensors & Smart Temperature Patches

Cardiovascular monitoring and diagnostic devices and equipment are used for the diagnosis, monitoring, and treatment of cardiovascular diseases. The main product types of cardiovascular monitoring and diagnostic devices and equipment are cardiopulmonary stress testing systems, ECG data management systems, ECG monitoring equipment, ECG stress testing systems, event monitoring systems, and Holter monitoring systems. ECG monitoring equipment is an electronic device that is used to record the electrical activity of the heart. The various types involved are heart disease and coronary heart disease. The various end-users involved are hospitals/physician clinics (continuous glucose monitors), home/emergency, and research and development (clinical trials, universities, CRO). The cardiovascular monitoring and diagnostic devices and equipment market research report is one of a series of new reports from The Business Research Company that provides cardiovascular monitoring and diagnostic devices and equipment market statistics, including cardiovascular monitoring and diagnostic devices and equipment industry global market size, regional shares, competitors with a cardiovascular monitoring and diagnostic devices and equipment market share, detailed cardiovascular monitoring and diagnostic devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the cardiovascular monitoring and diagnostic devices and equipment industry. This cardiovascular monitoring and diagnostic devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global cardiovascular monitoring and diagnostic devices and equipment market size will grow from $3.12 billion in 2022 to $3.36 billion in 2023 at a compound annual growth rate (CAGR) of 7.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cardiovascular monitoring and diagnostic devices and equipment market size is expected to grow to $4.31 billion in 2027 at a CAGR of 6.4%. The cardiovascular monitoring and diagnostic devices and equipment market is being driven by an increasing number of people suffering from obesity and diabetes. Risk factors including high blood pressure and high cholesterol are associated with obesity and diabetes leads to cardiovascular diseases. For instance, as per a study conducted by the American Heart Association (AMA), by 2030, 22.2 million CVD is expected to grow. According to another study conducted by AMA in the U.S., 26 million people have been diagnosed with diabetes, and above 9 million further, have the condition but it hasn't yet been diagnosed. The cardiovascular monitoring and diagnostic devices and equipment market is being restrained by the FDA's regulatory control over these devices based on the risks associated with this equipment. Cardiovascular monitoring and diagnostic devices fall into the class II category as per the FDA, which includes devices with moderate to high risk associated with usage. The Class II devices are specially controlled with performance standards which provide the manufacturers with performance specifications, postmarket surveillance which monitors the safety of the device after being released in the market, and also other standards like patient registries and special labeling requirements. For instance, Angel medical systems’ implantable cardiac monitor was unanimously rejected by a panel of FDA experts due to unmet performance specifications. ICMs continuously monitor the electrocardiogram (ECG) of the patient to conduct a real-time examination of the heart rhythm, for up to 36 months. ICMs are mostly used in the analysis of transitory symptoms which have an arrhythmic origin, such as unexplained palpitations. For example, in July 2020, Medtronic received U.S. Food and Drug Administration (FDA) clearance and European CE label approval for its Linq II insertable cardiac monitor (ICM) by remote programming, allowing clinicians to optimize device settings without the requirement for patients to return to the hospital. The launch of new products is a key trend gaining popularity in the cardiovascular monitoring and diagnostic devices and equipment market. Companies in the market are focusing on the launch of new products to improve their product portfolio and strengthen their market position. For example, in August 2022, SmartCardia SA, a medical equipment manufacturer in Switzerland, launched 7L patch, its 7-lead cardiac monitoring patch in India. This patch monitor combines medical wearable technology with artificial intelligence (AI) to provide predictive and personalized patient insights through remote monitoring. The 7L patch is tracked by SmartCardia’s AI platform is interpreted by cardiologists and certified cardiac technicians and performs real-time detection of important arrhythmia events at cardiologist level accuracy. The US FDA has classified cardiovascular monitoring and diagnostic devices into the Class II category, as they have a moderate to high risk associated with usage. Class II devices are bounded by device-specific regulations which include performance standards, premarket data requirements, postmarket surveillance, and labeling requirements associated with device usage. For instance, the labeling should consist of contraindications, adverse reactions, precautions, warnings, and other instructions before the device is released into the market. Major players in the cardiovascular monitoring and diagnostic devices and equipment market are Medtronic PLC., Boston Scientific Corporation, GE Healthcare, Johnson & Johnson, Philips Healthcare, Siemens Healthcare, St. Jude MedicalInc., Nihon Kohden Corporation, FUKUDA DENSHI Co. Ltd., and Sorin Group. North America was the largest region in global cardiovascular monitoring and diagnostic devices and equipment market in 2022. Western Europe was the second-largest region incardiovascular monitoring and diagnostic devices and equipment market. The regions covered in global cardiovascular monitoring and diagnostic devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cardiovascular monitoring and diagnostic devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. The cardiovascular monitoring and diagnostic devices and equipment market consist of sales of cardiopulmonary stress testing systems, ECG data management systems, ECG monitoring equipment, ECG stress testing systems, event monitoring systems, and holter monitoring systems that are used for diagnosis and treatment of cardio diseases. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global cardiovascular monitoring and diagnostic devices and equipment market is segmented - 1) By Product Type: Cardiopulmonary Stress Testing Systems, ECG Data Management Systems, ECG Monitoring Equipment, ECG Stress Testing Systems, Event Monitoring Systems, Holter Monitoring Systems 2) By End-Use: Hospitals/Physician Clinic (Continuous Glucose Monitors), Home/Emergency, Research and Development (Clinical Trials, Universities, CRO) 3) By Type: Heart Disease, Coronary Heart Disease

Voice prosthesis devices and equipment provide the capability to speak for patients who have undergone laryngectomy (removal of the larynx). These devices are placed in the tracheoesophageal puncture, an opening created between the trachea (windpipe) and the esophagus (food pipe) by surgeons. The main device types of voice prosthesis devices and equipment are indwelling voice prosthesis devices and non-indwelling voice prosthesis devices. Non-indwelling devices can be removed by the patient and changed, creating a higher level of independence for the patient. The product types used are soft valve assemblies, hard valve assemblies, and others. The valve types are Blom-Singer valve, Provox valve, and Groningen valve, which are made up of silicone rubber, silicone, fluoroplastic, silver oxide, and others. The various end-users are hospitals, ambulatory surgical centres, and clinics. The voice prosthesis devices and equipment market research report is one of a series of new reports from The Business Research Company that provides voice prosthesis devices and equipment market statistics, including voice prosthesis devices and equipment industry global market size, regional shares, competitors with a voice prosthesis devices and equipment market share, detailed voice prosthesis devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the voice prosthesis devices and equipment industry. This voice prosthesis devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global voice prosthesis devices and equipment market size will grow from $1.57 billion in 2022 to $1.77 billion in 2023 at a compound annual growth rate (CAGR) of 12.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The voice prosthesis devices and equipment market size is expected to grow to $2.69 billion in 2027 at a CAGR of 11.0%. The voice prosthesis device and equipment market is driven by an increasing number of cases of larynx cancer. Larynx cancer is a disease in which cancer cells form tissue in the larynx and cause a sore throat and ear pain. According to the WHO, there were 99840 deaths reported in 2020 due to Larynx cancer. High equipment cost of voice prosthesis devices and equipment hampers the voice prosthesis devices and equipment market growth. High equipment costs refer to the replacement of prosthesis devices and equipment after a certain period. For instance, the JAMA Otolaryngol Head Neck Surgery center found that the average life of the prosthesis devices and equipment is 3-6 months after which the device has to be changed. Technological advancements of voice prosthesis devices and equipment have increased various properties of devices including, a lifetime of the device, simple and easy maintenance by patients, and comfortable outpatient replacements. For instance, the Indwelling prostheses are designed to meet the criteria of low air resistance and optimal retention in the tracheoesophageal wall, these prostheses devices and equipment have become the valve of choice with the success rate of 40-90% having very good voice quality. Medical devices including ENT surgical devices enter the market through FDA 510(K) premarket clearance pathway, As announced by the FDA, this regulation is set to undergo changes in which more efficient medical devices clearance process to introduce a new generation of safety, technology, and capabilities in medical devices. The EU’s Medical Device Regulation (MDR) came into force in 2020. The future of ENT devices is likely to be impacted by both modernizations of the FDA 510(k) pathway and the forthcoming enforcement of new EU MDR regulations. In September 2021, Atos Medical, a US-based company, a specialist in laryngectomy care-acquired TRACOE medical for an undisclosed amount. This acquisition is combining companies will strengthen the ability to fast track the journey towards becoming a full range global player in the tracheostomy segment, through a combined hospital and direct-to-consumer model. TRACOE medical is a Germany-based manufacturer of medical technology. Major players in the voice prosthesis devices and equipment market are Atos Medical, Andreas Fahl Medizintechnik–Vertrieb, Servona, Acclarent Inc., (A Subsidiary of Johnson & Johnson), Karl Storz Gmbh & Co. Kg, Smith & Nephew PLC., InHealth Technologies, HEIMOMED Heinze, Sonova Holding AG, and William Demant Holding A/S. North America was the largest region in the global voice prosthesis devices and equipment market in 2022. Asia-Pacific was the second-largest region in the voice prosthesis devices and equipment market. The regions covered in the global voice prosthesis devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the voice prosthesis devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. The vice prosthesis devices and equipment market consist of sales of indwelling voice prosthesis devices and non-indwelling voice prosthesis devices. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global voice prosthesis devices and equipment market is segmented - 1) By Device Type: Indwelling Voice Prosthesis Devices, Non-Indwelling Voice Prosthesis Devices 2) By Product Type: Soft Valve Assembly, Hard Valve Assembly, Other Product Types 3) By Valve Type: Blom-Singer valve, Provox valve, Groningen valve 4) By Material: Silicone Rubber, Silicone, Fluoroplastic, Silver Oxide, Other Materials 5) By End User: Hospitals, Ambulatory Surgical Centers, Clinics

The antidiarrheal drugs refer to drugs that relieve the frequent passing of a watery, loose stool, one of the symptoms of diarrhoea. According to their shared chemical or functional properties, antidiarrheal medications can generally be grouped into three groups: adsorbents, antimotility agents, and bacterial replacements (probiotics). The main classes of antidiarrhoeals drugs are mucosal protectants and motility modifying drugs. Mucosal protective agents are drugs that safeguard the stomach’s mucosal lining from gastric acid and are employed to cure peptic ulcers. The different types include OTC drugs, and prescription drugs, which are used by adults and children. The antidiarrheal drugs market research report is one of a series of new reports from The Business Research Company that provides antidiarrheal drugs market statistics, including antidiarrheal drugs industry global market size, regional shares, competitors with antidiarrheal drugs market share, detailed antidiarrheal drugs market segments, market trends and opportunities, and any further data you may need to thrive in the antidiarrheal drugs industry. This antidiarrheal drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global antidiarrhoeals market size will grow from $3.81 billion in 2022 to $3.94 billion in 2023 at a compound annual growth rate (CAGR) of 3.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global antidiarrhoeals market size is expected to grow to $4.31 billion in 2027 at a CAGR of 2.3%. The rise in the number of diarrhea cases significantly contributes to the growth of the antidiarrheal drug market. According to UNICEF, diarrhea was the second leading cause of death among children under the age of 5 years that is responsible for killing 760,000 children every year. An increasing number of diarrheal cases increases the demand for antidiarrheal drugs. An increase in the use of biologics medicines poses to be a restraint to the antidiarrheal market. Biologics are medicines derived from living organisms like human beings, animals, or other microorganisms using biotechnology and are composed of proteins, sugar, nucleic acids, or a combination of each of these substances. Due to their ability to target inaccessible parts using small-molecule therapies, biologics are being preferred over traditional chemical drugs. This shift is restricting the antidiarrheal drugs market hampering its growth of the market. For example, to treat Crohn’s Disease, antidiarrheal medications were being used previously, but with the advent of biologics, demand for antidiarrheal diseases has subsided. Major companies in the antidiarrheal drug market are merging with other companies in the market to increase their reach and market share. Companies merge with or acquire other companies to expand their market share, diversify their product portfolio, or acquire new technologies. For instance, GlaxoSmithKline agreed to acquire Novartis AG's 36.5% stake in the consumer healthcare business for $ 13 billion to expand the market. The antidiarrheal drug industry is governed by regulatory frameworks by agencies such as US Food and Drug Administration Agency (FDA). FDA's guidelines for antidiarrheal drugs are mentioned within the CFR's (Code for Federal Regulations) title number 21 under part 335 which gives guidelines for the over-the-counter (OTC) human use of the antidiarrheal drugs. Subpart C of the regulation focuses on the labeling aspect of such drugs and mandates a statement of identity, which identifies the product is to be used for diarrhea to avoid any improper use of the drug. The FDA also regulates the warnings and directions of use of the drugs which are to be printed on the cover of these drugs. In March 2020, Arcadia Consumer Healthcare, Inc., a USA-based pharmaceutical company acquired the Kaopectate brand from Sanofi for an undisclosed amount. This acquisition enhanced Sanofi’s product portfolio by providing consumers with simple, efficacious, and high-quality solutions. Sanofi, is a France-based biopharmaceutical company focused on human health. Major players in the antidiarrhoeals market are GlaxoSmithKline, Actelion, Perrigo, Lupin and Glenmark Pharmaceuticals, Merck & Co., Pfizer, Proctor & Gamble, Sanofi Aventis and Bayer. North America was the largest region in the antidiarrhoeals market in 2022. The regions covered in the global antidiarrhoeals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the antidiarrhoeals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The antidiarrheal drugs market consists of sales loperamide hydrochloride, Bismuth subsalicylate, Pepto Bismol and Imodium. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global antidiarrhoeals market is segmented - 1) By Drug Class: Mucosal Protectants, Motility Modifying Drugs 2) By Application: Adults, Childrens 3) By Type: OTC drugs, Prescription Drugs

The musculoskeletal disorders drugs market consists of sales of musculoskeletal disorders drugs and related services by entities (organizations, sole traders and partnerships) that produce musculoskeletal disorders drugs to treat musculoskeletal disorders such as arthritis, osteoporosis, osteomalacia, and other disorders. This industry includes establishments that produce drugs to treat rheumatoid arthritis, muscle relaxants to reduce muscle pain, and other drugs used in treating osteoarthritis, analgesics drugs, immunosuppressive. Some of the major drugs in the market include Piroxicam Glaxo, Dolonex, Felden, and Piroxicam Pfizer. The main types of musculoskeletal disorders drugs are drugs for rheumatoid arthritis, muscle relaxants and other musculoskeletal disorders drugs. A muscle relaxant is a medication that causes muscle contractions to cease. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores and others. The global musculoskeletal disorders drugs market size is expected to grow from $897.45 billion in 2021 to $104.03 billion in 2022 at a compound annual growth rate (CAGR) of 6.8%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The musculoskeletal disorders drugs market is expected to reach $163.94 billion in 2026 at a CAGR of 12%. The aging population profile of most countries contributed to the growth of the musculoskeletal disorders drugs market. The increase in patient pool due to rising geriatric population globally, contributed significantly to the growth of the market during the historic period. According to the WHO, by 2030, one in every six people on the planet will be 60 or older. The proportion of the population aged 60 and up will rise from 1 billion in 2020 to 2.1 billion by 2050. This rise in the geriatric population increased the demand for medical care and drove the healthcare expenditure. This has led to increased demand for pharmaceuticals products, significantly impacting market growth during this period. Regulatory changes are likely to lead to increased costs relating to new product development and service offerings to clients. These changes are related to data protection such as the European Union's General Data Protection Regulation (GDPR), changes to drug approval procedures and other regulatory changes. For instance, according to a study on 100 Data Privacy and Data Security statistics for 2020, GDPR compliance is a top priority for 58% of European companies. The GDPR regulation is a EU law on data protection and privacy of individuals residing the European Union and the European Economic Area (EEA). It also regulates data anonymization thus maintaining integrity of data dealing with patients and other clinical trial studies. The potential loss of revenue due to delays in product release and additional costs incurred due to stringent approval processes puts strain to investments relating to new product development, thereby affecting the growth of the musculoskeletal disorders drugs market. Going forward, the market for muscle relaxants is expected to increase with the rise in combination therapy. Combination therapy involves use of more than one medication or drug to treat a disease. These combinational therapies reduce the frequency of drug administration. For instance, in May 2019, Galt Pharmaceuticals has submitted a Supplemental Abbreviated New Drug Application to the U.S. Food and Drug Administration for Orphengesic Forte an oral formulation of aspirin, caffeine, and orphenadrine for the treatment of pain caused due to musculoskeletal disorders. Major companies in the musculoskeletal disorders drugs market include Sanofi S.A, Pfizer Inc., Bristol-Myers Squibb, Eli Lilly And Company, Mitsubishi Tanabe Pharma Corporation, Horizon Therapeutics plc, Procter & Gamble, Eisai Co. Ltd, Biogen Inc and Sino Biopharmaceutical. North America was the largest region in the musculoskeletal disorders drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the musculoskeletal disorders drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the musculoskeletal disorders drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global musculoskeletal disorders drugs market is segmented - 1) By Type: Drugs for Rheumatoid Arthritis, Muscle Relaxants, Other Musculoskeletal Disorders Drugs 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs